{
    "info": {
        "nct_id": "NCT05417594",
        "official_title": "A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)",
        "inclusion_criteria": "* Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks.\n* Progressive cancer at the time of study entry.\n* Adequate organ and marrow function.\n\nModule 1:\n\n* Female participants of childbearing potential:\n\n  1. Must have a negative pregnancy test result at screening and prior to each cycle of study treatment.\n  2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment.\n* Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment.\n* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 3 months after the last dose of study intervention.\n* Female partners of male participants should use at least one highly effective method of contraception from screening to approximately 3 months after the last dose of study intervention of the male participant.\n* Male participants must refrain from fathering a child or donating sperm from the start of study intervention and for approximately 3 months after the last dose of study intervention.\n\nPart A:\n\n- Participants must have one of the following: (i) Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii) Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.\n\n(iii) Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes:BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (d) Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.\n\n* Participants must have evaluable disease.\n* Patients must be suitable for treatment with a PARPi.\n* Participants must be capable of eating a high fat meal and adhering to fasting restrictions.\n\nPart B:\n\n* Participants must have metastatic or recurrent locally advanced histologically or cytologically confirmed Human Epidermal growth factor Receptor 2 (HER2)-negative carcinoma of the breast and evidence of a predicted loss of function germline or tumour mutation.\n* Participants must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.\n* Participants who have received platinum chemotherapy for advanced breast cancer are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy.\n* Participants who have received prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention.\n\nModule 2:\n\n* Participants must be suitable for treatment with TMZ.\n* Participants must have IDH1/2-mutant glioma.\n* Participants should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.\n* Recurrent disease must be evaluable by MRI.\n* Female participants of childbearing potential must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ.\n* Adequate organ and marrow function.\n\nModule 3:\n\nAll Panels:\n\n* Female participants of childbearing potential:\n\n  1. Must have a negative pregnancy test result at screening and prior to each cycle of study treatment.\n  2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment.\n* Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment.\n\nPanel 1\n\n* Participants must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.\n* Participants must have one of the following:\n\n  1. Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D,\n  2. Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D\n  3. Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D\n  4. Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.\n* Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1\n* Participants must be refractory to standard therapy or for which no standard therapy exists.\n* Any 2 participants in this panel must meet the following CNS criteria:\n\n  1. Participants must have previously treated and progressing or untreated brain metastases confirmed by brain MRI at screening that do not need immediate local therapy.\n  2. Participants should have stable neurological function for ≥ 14 days prior to signing the main study ICF.\n  3. If receiving steroids, the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF.\n\nPanel 2\n\n* Participants must be suitable for treatment with TMZ.\n* Participants must have IDH1/2-mutant glioma.\n* Participants should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.\n* Recurrent disease must be evaluable by MRI and at least 1 tumour of > 1cm diameter detected on MRI.\n* Formalin-fixed, paraffin-embedded (FFPE) tumour sample from the primary cancer must be available for central testing\n* Adequate organ and marrow function (in the absence of transfusions or growth factor support within 14 days prior to enrolment)\n\nPanel 3\n\n* Participants must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.\n* Participants must have histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D .\n* Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1 .\n* Participants must be refractory to standard therapy or for which no standard therapy exists.\n\nModule 4:\n\n* Participants must have the following HER2 status:\n\n  1. Participants with breast cancer must be IHC 3+ or IHC 2+/ISH-positive or IHC 2+/ISH-negative or IHC 1+ as determined by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring HER2 + breast cancer.\n  2. Participants with gastric cancer should be IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results.\n  3. Participants with non-breast and non-gastric cancers must have HER2-overexpression (IHC 3+ or IHC 2+; as determined by local testing using current ASCO-CAP guidelines for gastric IHC scoring).\n  4. Participants with NSCLC will also be eligible based on the presence of a HER2activating mutation.\n* Participants must have progressed following at least one prior systemic treatment and not more than 2 prior lines of cytotoxic therapy for metastatic or advanced disease and have no satisfactory alternative treatment option.\n* Participants should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: Breast cancer, Non-Small Cell Lung Cancer, Colorectal Cancer,Bladder Cancer, Ovarian Cancer, Gastric Cancer, and Other tumour types ( unresectable or metastatic biliary tract cancer, cervical cancer, endometrial cancer, and pancreatic adenocarcinoma).\n* Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.\n* Left ventricular ejection fraction (LVEF) ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before start of treatment.\n* Participants must have at least one lesion not previously irradiated (or with evidence of disease progression following radiation).\n* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 6 months after the last dose of study intervention.\n* Male participants must refrain from fathering a child or donating sperm during the study and for approximately 6 months after the last dose of study intervention.\n\nModule 5 :\n\n* Participants should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: TNBC, Endometrial cancer, Ovarian Cancer and CRPC.\n* Participants must have progressed following at least one prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment option.\n* Participants must have at least one lesion, not previously irradiated that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.\n* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to at least 4 months after the last dose of study.\n* Male participants must refrain from fathering a child or donating sperm during the study and for at least 4 months after the last dose of study intervention.\n* Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.\n\nModule 4 & 5:\n\n* Female participants of childbearing potential:\n\n  1. Must have a negative pregnancy test result at screening and prior to each cycle of study intervention.\n  2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control in combination with one effective method (male condom plus spermicide) from screening until at least 7 months after the last dose of study intervention\n* Female participants must not breastfeed and must not donate or retrieve ova for any use from screening to at least 7 months after the last dose of study intervention.\n* Participants must provide an existing FFPE tumour sample for retrospective, tissue-based IHC testing in a central laboratory to determine HER2 expression and other correlatives.\n* ECOG performance status of 0 or 1.\n* Participants recruited specifically for PD evaluation must have at least 1 tumour suitable for paired biopsies and be willing to consent to pre-treatment and on-treatment biopsies.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
        "exclusion_criteria": "* Major surgery within 4 weeks of the first dose of study intervention.\n* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.\n* With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study intervention.\n* Any known history of persisting severe pancytopenia due to any cause.\n* Spinal cord compression unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.\n* History of uncontrolled seizures or with need for concurrent administration of more than 2 antiepileptic drugs, or history of epileptic disorder or any seizure history unrelated to tumour.\n* History of severe brain injury or stroke.\n* Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).\n* Uncontrolled intercurrent illness within the last 12 months.\n* Any known predisposition to bleeding.\n* Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574.\n* Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).\n* Known contra-indication to gadolinium-enhanced Magnetic Resonance Imaging (MRI) or, if applicable, not able to be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 7 days) prior to the baseline MRI.\n* Any concurrent anti-cancer therapy or concurrent use of prohibited medications.\n\nModule 1:\n\nPart A:\n\n* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen.\n* Participants with an INR >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.\n* Participants with leptomeningeal disease (LMD) unless the LMD is of low volume or is previously treated and the participant is asymptomatic or minimal symptoms.\n* Participants with insulin-dependent diabetes.\n* Participants currently on ARA treatment.\n\nPart B:\n\n* Participants with an International Normalised Ratio (INR) >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.\n* Participants with LMD are excluded unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD.\n\nModule 2:\n\n* Participants who have received a PARPi previously.\n* Known hypersensitivity to TMZ or dacarbazine or known history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9574.\n* Participants who have received > 1 prior line of alkylating chemotherapy regimen.\n* Participants who had previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy.\n* Participants who have received bevacizumab within the last 6 months.\n* Not requiring continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.\n\nModule 3:\n\nAll Panels\n\n* Positive Allen's test\n* Participants with a BMI > 30.0 kg/m2 or body weight > 100.0 kg\n* Participants who suffer from claustrophobia.\n* Participants with implanted metal devices or implants containing metal\n* Participants with an INR >1.5\n* Participants taking acid-reducing agents.\n\nPanel 1\n\n* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen .\n* Participants with leptomeningeal disease (LMD)\n\nPanel 2\n\n* Participants who have received a PARPi previously.\n* Known hypersensitivity to TMZ.\n* Participants who have received > 1 prior line of alkylating chemotherapy regimen.\n* Participants who had previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy.\n* Participants who have received bevacizumab within the last 6 months.\n\nPanel 3\n\n* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen.\n* Participants with LMD\n\nModule 4:\n\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of T-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.\n* Participants should not have received more than 2 prior lines of systemic cytotoxic therapy.\n* Prior treatment with HER2 directed TOPO1i ADCs and prior AZD9574 is not permitted.\n* Participants must not enter the study if they received chloroquine/hydroxychloroquine < 14 days prior to the first dose.\n* Presence of unresolved toxicities from previous anti-cancer therapy, defined as toxicities not yet resolved to Grade ≤ 1 or baseline.\n* Participants with a known history of prior platelet transfusion(s) or febrile neutropenia in the advanced disease treatment setting.\n* Participants with medical history of myocardial infarction. Participants with troponin levels above ULN at screening and without any myocardial related symptoms.\n* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis.\n* Additional lung-related exclusion criteria: (a) Lung-specific intercurrent clinically significant illnesses (b) Any autoimmune, connective tissue or inflammatory disorders (c) Prior pneumonectomy.\n* Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy.\n* Participants with a known hypersensitivity to T-DXd, any the excipients or other mAbs.\n* History of another primary malignancy.\n* Participants with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.\n* Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or hepatitis C infection.\n\nModule 5:\n\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of Dato-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.\n* Corticosteroid mouthwash formulations are permitted to prevent and manage certain AEs.\n* Prior anti-cancer treatments:\n\n  (d) Participants should not have received more than 2 prior lines of systemic cytotoxic therapy (e) Prior treatment with PARPi is permitted (f) Prior TOPO1 inhibitor therapy is NOT permitted (g) Prior treatment with TROP2-directed ADCs is NOT permitted. (h) Prior radiation therapy requires the washout periods.\n* Participants must not enter the study if they received chloroquine / hydroxychloroquine < 14 days prior to the first dose.\n* History of another primary malignancy.\n* Participant has history of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current or suspected ILD/pneumonitis.\n* Clinically severe pulmonary function compromise.\n* Clinically significant corneal disease.\n* History of severe hypersensitivity reactions to Dato-DXd, or any of the excipients of the product.\n* History of severe hypersensitivity reactions to other monoclonal antibodies.\n* Participant is pregnant or breastfeeding or planning to become pregnant.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Participants who have received platinum chemotherapy for advanced breast cancer are eligible to enter the study provided there has been no evidence of disease progression during the platinum chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received platinum chemotherapy for advanced breast cancer",
                    "criterion": "receipt of platinum chemotherapy for advanced breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no evidence of disease progression during the platinum chemotherapy",
                    "criterion": "disease progression during platinum chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "evidence of progression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be suitable for treatment with TMZ.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be suitable for treatment with TMZ.",
                    "criterion": "suitability for treatment with TMZ",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "All Panels:",
            "criterions": [
                {
                    "exact_snippets": "All Panels:",
                    "criterion": "panel inclusion",
                    "requirements": [
                        {
                            "requirement_type": "panel",
                            "expected_value": "all"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have one of the following:",
            "criterions": [
                {
                    "exact_snippets": "Participants must have one of the following:",
                    "criterion": "diagnosis (unspecified)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have at least one lesion not previously irradiated (or with evidence of disease progression following radiation).",
            "criterions": [
                {
                    "exact_snippets": "at least one lesion not previously irradiated (or with evidence of disease progression following radiation)",
                    "criterion": "lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "irradiation status",
                            "expected_value": "not previously irradiated or with evidence of disease progression following radiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female partners of male participants should use at least one highly effective method of contraception from screening to approximately 3 months after the last dose of study intervention of the male participant.",
            "criterions": [
                {
                    "exact_snippets": "Female partners of male participants should use at least one highly effective method of contraception from screening to approximately 3 months after the last dose of study intervention of the male participant.",
                    "criterion": "contraception use by female partners of male participants",
                    "requirements": [
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "highly effective"
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "method"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening to approximately 3 months after the last dose of study intervention of the male participant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 3",
            "criterions": [
                {
                    "exact_snippets": "Panel 3",
                    "criterion": "panel 3",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have progressed following at least one prior systemic treatment and not more than 2 prior lines of cytotoxic therapy for metastatic or advanced disease and have no satisfactory alternative treatment option.",
            "criterions": [
                {
                    "exact_snippets": "must have progressed following at least one prior systemic treatment",
                    "criterion": "progression after prior systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "number of prior systemic treatments with progression",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not more than 2 prior lines of cytotoxic therapy for metastatic or advanced disease",
                    "criterion": "number of prior lines of cytotoxic therapy for metastatic or advanced disease",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "have no satisfactory alternative treatment option",
                    "criterion": "satisfactory alternative treatment option",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.",
            "criterions": [
                {
                    "exact_snippets": "progressive disease after prior radiation therapy",
                    "criterion": "disease progression after radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressive after prior radiation therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "one prior line of alkylating chemotherapy for their disease",
                    "criterion": "prior alkylating chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "chemotherapy type",
                            "expected_value": "alkylating"
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "relapse status",
                            "expected_value": "relapsed"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": "advanced"
                        },
                        {
                            "requirement_type": "cancer type",
                            "expected_value": [
                                "ovarian",
                                "fallopian tube",
                                "primary peritoneal"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part B:",
            "criterions": [
                {
                    "exact_snippets": "Part B",
                    "criterion": "trial part enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "Part B"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of transfusions or growth factor support",
                    "criterion": "transfusion support",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of transfusions or growth factor support",
                    "criterion": "growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days prior to the first dose of study intervention",
                    "criterion": "timing of assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "(iii) Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes:BRCA1, BRCA2, PALB2, RAD51C, or RAD51D (d) Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC)",
                    "criterion": "castration-resistant prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes:BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "homologous recombination repair gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "BRCA1",
                                "BRCA2",
                                "PALB2",
                                "RAD51C",
                                "RAD51D"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologically or cytologically confirmed advanced/metastatic pancreatic cancer",
                    "criterion": "pancreatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "homologous recombination repair gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "BRCA1",
                                "BRCA2",
                                "PALB2",
                                "RAD51C",
                                "RAD51D"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 3 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Non-sterilised male participants",
                    "criterion": "male sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active with a female partner of childbearing potential",
                    "criterion": "sexual activity with female partner of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use a condom with spermicide from screening to approximately 3 months after the last dose of study intervention",
                    "criterion": "condom with spermicide use",
                    "requirements": [
                        {
                            "requirement_type": "use of condom with spermicide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening to approximately 3 months after the last dose of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function (in the absence of transfusions or growth factor support within 14 days prior to enrolment)",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of transfusions or growth factor support within 14 days prior to enrolment",
                    "criterion": "transfusions or growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 14,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants with breast cancer must be IHC 3+ or IHC 2+/ISH-positive or IHC 2+/ISH-negative or IHC 1+ as determined by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring HER2 + breast cancer.",
            "criterions": [
                {
                    "exact_snippets": "Participants with breast cancer",
                    "criterion": "breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "IHC 3+ or IHC 2+/ISH-positive or IHC 2+/ISH-negative or IHC 1+ as determined by local testing using current American Society of Clinical Oncology-College of American Pathologists (ASCO-CAP) guidelines for scoring HER2 + breast cancer",
                    "criterion": "HER2 status (by IHC/ISH)",
                    "requirements": [
                        {
                            "requirement_type": "IHC/ISH result",
                            "expected_value": [
                                "IHC 3+",
                                "IHC 2+/ISH-positive",
                                "IHC 2+/ISH-negative",
                                "IHC 1+"
                            ]
                        },
                        {
                            "requirement_type": "testing method",
                            "expected_value": "local testing using current ASCO-CAP guidelines"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 130 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 130 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 130,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants should have stable neurological function for ≥ 14 days prior to signing the main study ICF.",
            "criterions": [
                {
                    "exact_snippets": "stable neurological function for ≥ 14 days prior to signing the main study ICF",
                    "criterion": "neurological function",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration_of_stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have IDH1/2-mutant glioma.",
            "criterions": [
                {
                    "exact_snippets": "IDH1/2-mutant glioma",
                    "criterion": "glioma",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "IDH1 or IDH2 mutant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential:",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                },
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be refractory to standard therapy or for which no standard therapy exists.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be refractory to standard therapy",
                    "criterion": "refractoriness to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no standard therapy exists",
                    "criterion": "availability of standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "existence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.",
            "criterions": [
                {
                    "exact_snippets": "Participants must consent to provide mandated blood samples",
                    "criterion": "blood sample",
                    "requirements": [
                        {
                            "requirement_type": "consent to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must consent to provide ... archival/fresh tumour tissue",
                    "criterion": "tumour tissue",
                    "requirements": [
                        {
                            "requirement_type": "consent to provide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmatory tests of their cancer using central laboratory",
                    "criterion": "cancer confirmatory testing",
                    "requirements": [
                        {
                            "requirement_type": "testing method",
                            "expected_value": "central laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group performance status (ECOG PS) with no deterioration over the previous 2 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group performance status (ECOG PS)",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "no deterioration over the previous 2 weeks",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "change over previous 2 weeks",
                            "expected_value": "no deterioration"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must provide an existing FFPE tumour sample for retrospective, tissue-based IHC testing in a central laboratory to determine HER2 expression and other correlatives.",
            "criterions": [
                {
                    "exact_snippets": "Participants must provide an existing FFPE tumour sample",
                    "criterion": "FFPE tumour sample",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": "FFPE"
                        }
                    ]
                },
                {
                    "exact_snippets": "retrospective, tissue-based IHC testing in a central laboratory to determine HER2 expression and other correlatives",
                    "criterion": "HER2 expression and other correlatives (by IHC)",
                    "requirements": [
                        {
                            "requirement_type": "test type",
                            "expected_value": "IHC"
                        },
                        {
                            "requirement_type": "testing location",
                            "expected_value": "central laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part A:",
            "criterions": [
                {
                    "exact_snippets": "Part A",
                    "criterion": "study part enrollment",
                    "requirements": [
                        {
                            "requirement_type": "enrollment",
                            "expected_value": "Part A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 2",
            "criterions": [
                {
                    "exact_snippets": "Panel 2",
                    "criterion": "panel assignment",
                    "requirements": [
                        {
                            "requirement_type": "assignment",
                            "expected_value": "Panel 2"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be suitable for treatment with TMZ.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be suitable for treatment with TMZ.",
                    "criterion": "suitability for treatment with TMZ",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must be suitable for treatment with a PARPi.",
            "criterions": [
                {
                    "exact_snippets": "suitable for treatment with a PARPi",
                    "criterion": "suitability for PARP inhibitor treatment",
                    "requirements": [
                        {
                            "requirement_type": "suitability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Female participants must not breastfeed",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment",
                    "criterion": "ova donation or retrieval for own use",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from screening to approximately 6 months after the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Progressive cancer at the time of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Progressive cancer at the time of study entry",
                    "criterion": "cancer progression status",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "If sexually active with a non-sterilised male partner",
                    "criterion": "sexual activity with a non-sterilised male partner",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "methods_required",
                            "expected_value": [
                                "at least one highly effective method of birth control",
                                "a barrier method"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening to approximately 6 months after the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have the following HER2 status:",
            "criterions": [
                {
                    "exact_snippets": "Participants must have the following HER2 status:",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC) and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed advanced/metastatic castration-resistant prostate cancer (CRPC)",
                    "criterion": "prostate cancer (CRPC)",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "disease stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "castration resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
                    "criterion": "mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: Breast cancer, Non-Small Cell Lung Cancer, Colorectal Cancer,Bladder Cancer, Ovarian Cancer, Gastric Cancer, and Other tumour types ( unresectable or metastatic biliary tract cancer, cervical cancer, endometrial cancer, and pancreatic adenocarcinoma).",
            "criterions": [
                {
                    "exact_snippets": "unresectable, or metastatic disease based on most recent imaging",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "most recent imaging"
                        }
                    ]
                },
                {
                    "exact_snippets": "The following tumour types are eligible for this study: Breast cancer, Non-Small Cell Lung Cancer, Colorectal Cancer,Bladder Cancer, Ovarian Cancer, Gastric Cancer, and Other tumour types ( unresectable or metastatic biliary tract cancer, cervical cancer, endometrial cancer, and pancreatic adenocarcinoma)",
                    "criterion": "tumour type",
                    "requirements": [
                        {
                            "requirement_type": "inclusion_list",
                            "expected_value": [
                                "Breast cancer",
                                "Non-Small Cell Lung Cancer",
                                "Colorectal Cancer",
                                "Bladder Cancer",
                                "Ovarian Cancer",
                                "Gastric Cancer",
                                "biliary tract cancer",
                                "cervical cancer",
                                "endometrial cancer",
                                "pancreatic adenocarcinoma"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ.",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test result at screening and prior to each cycle administration of AZD9574 and TMZ",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to each cycle administration of AZD9574 and TMZ"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participants with NSCLC will also be eligible based on the presence of a HER2activating mutation.",
            "criterions": [
                {
                    "exact_snippets": "Participants with NSCLC",
                    "criterion": "NSCLC",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "presence of a HER2activating mutation",
                    "criterion": "HER2 activating mutation",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ and marrow function (in the absence of transfusions or growth factor support) within 14 days prior to the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the absence of transfusions or growth factor support",
                    "criterion": "transfusions or growth factor support",
                    "requirements": [
                        {
                            "requirement_type": "absence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "within 14 days prior to the first dose of study intervention",
                    "criterion": "timing of assessment",
                    "requirements": [
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have at least one lesion, not previously irradiated that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.",
            "criterions": [
                {
                    "exact_snippets": "at least one lesion",
                    "criterion": "lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously irradiated",
                    "criterion": "lesion irradiation history",
                    "requirements": [
                        {
                            "requirement_type": "previous irradiation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "can be accurately measured at baseline as ≥ 10 mm in the longest diameter",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must consent to provide mandated blood samples and archival/fresh tumour tissue for confirmatory tests of their cancer using central laboratory.",
            "criterions": [
                {
                    "exact_snippets": "Participants must consent to provide mandated blood samples",
                    "criterion": "blood sample provision",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants must consent to provide ... archival/fresh tumour tissue",
                    "criterion": "archival/fresh tumour tissue provision",
                    "requirements": [
                        {
                            "requirement_type": "consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "provision",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "confirmatory tests of their cancer using central laboratory",
                    "criterion": "cancer confirmatory testing in central laboratory",
                    "requirements": [
                        {
                            "requirement_type": "testing location",
                            "expected_value": "central laboratory"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. If receiving steroids, the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF.",
            "criterions": [
                {
                    "exact_snippets": "If receiving steroids, the dose should be stable or decreasing for ≥ 14 days prior to signing the main study ICF.",
                    "criterion": "steroid dose",
                    "requirements": [
                        {
                            "requirement_type": "trend",
                            "expected_value": [
                                "stable",
                                "decreasing"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants must refrain from fathering a child or donating sperm from the start of study intervention and for approximately 3 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Male participants must refrain from fathering a child ... from the start of study intervention and for approximately 3 months after the last dose of study intervention.",
                    "criterion": "fathering a child",
                    "requirements": [
                        {
                            "requirement_type": "refrain period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "from start of study intervention to 3 months after last dose"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male participants must refrain from ... donating sperm from the start of study intervention and for approximately 3 months after the last dose of study intervention.",
                    "criterion": "donating sperm",
                    "requirements": [
                        {
                            "requirement_type": "refrain period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0,
                                "unit": "from start of study intervention to 3 months after last dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "If sexually active with a non-sterilised male partner",
                    "criterion": "sexual activity with a non-sterilised male partner",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use at least one highly effective method of birth control plus a barrier method from screening to approximately 6 months after the last dose of study treatment",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "method type",
                            "expected_value": [
                                "at least one highly effective method of birth control",
                                "plus a barrier method"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening to approximately 6 months after the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be refractory to standard therapy or for which no standard therapy exists.",
            "criterions": [
                {
                    "exact_snippets": "Participants must be refractory to standard therapy",
                    "criterion": "refractoriness to standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for which no standard therapy exists",
                    "criterion": "availability of standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "existence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Formalin-fixed, paraffin-embedded (FFPE) tumour sample from the primary cancer must be available for central testing",
            "criterions": [
                {
                    "exact_snippets": "Formalin-fixed, paraffin-embedded (FFPE) tumour sample from the primary cancer must be available",
                    "criterion": "FFPE tumour sample from the primary cancer",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for central testing",
                    "criterion": "FFPE tumour sample from the primary cancer",
                    "requirements": [
                        {
                            "requirement_type": "intended use",
                            "expected_value": "central testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recurrent disease must be evaluable by MRI.",
            "criterions": [
                {
                    "exact_snippets": "Recurrent disease must be evaluable by MRI",
                    "criterion": "recurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "evaluability by MRI",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Must have a negative pregnancy test result at screening and prior to each cycle of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "negative pregnancy test result at screening",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative pregnancy test result ... prior to each cycle of study treatment",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "prior to each cycle of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0 or 1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Must have a negative pregnancy test result at screening and prior to each cycle of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "negative pregnancy test result at screening and prior to each cycle of study intervention",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": [
                                "at screening",
                                "prior to each cycle of study intervention"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 1",
            "criterions": [
                {
                    "exact_snippets": "Panel 1",
                    "criterion": "panel 1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D,",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed HER2-negative carcinoma of the breast",
                    "criterion": "breast carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent locally advanced or metastatic disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "recurrent locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment are eligible provided at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment",
                    "criterion": "prior platinum-based chemotherapy as neo-adjuvant/adjuvant treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 12 months have elapsed between the last dose of platinum-based treatment and first dose of study intervention",
                    "criterion": "time since last platinum-based treatment",
                    "requirements": [
                        {
                            "requirement_type": "elapsed time",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D .",
            "criterions": [
                {
                    "exact_snippets": "histologically or cytologically confirmed HER2-negative carcinoma of the breast",
                    "criterion": "breast carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "recurrent locally advanced or metastatic disease",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "recurrent locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
                    "criterion": "mutation in BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Histologically or cytologically confirmed advanced/metastatic pancreatic cancer and evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed advanced/metastatic pancreatic cancer",
                    "criterion": "pancreatic cancer",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "origin",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have IDH1/2-mutant glioma.",
            "criterions": [
                {
                    "exact_snippets": "IDH1/2-mutant glioma",
                    "criterion": "glioma",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "IDH1 or IDH2 mutant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to at least 4 months after the last dose of study.",
            "criterions": [
                {
                    "exact_snippets": "Non-sterilised male participants",
                    "criterion": "sterilization status (male)",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active with a female partner of childbearing potential",
                    "criterion": "sexual activity with female partner of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use a condom with spermicide from screening to at least 4 months after the last dose of study",
                    "criterion": "condom with spermicide use",
                    "requirements": [
                        {
                            "requirement_type": "use of condom with spermicide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "screening to at least 4 months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Participants must have previously treated and progressing or untreated brain metastases confirmed by brain MRI at screening that do not need immediate local therapy.",
            "criterions": [
                {
                    "exact_snippets": "previously treated and progressing or untreated brain metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": [
                                "previously treated and progressing",
                                "untreated"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "brain metastases confirmed by brain MRI at screening",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "brain MRI at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "do not need immediate local therapy",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "need for immediate local therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1",
            "criterions": [
                {
                    "exact_snippets": "Participants must have evaluable disease",
                    "criterion": "evaluable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one measurable and/or non-measurable lesions per RECIST 1.1",
                    "criterion": "lesions (measurable and/or non-measurable) per RECIST 1.1",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "RECIST 1.1 criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should have progressive disease after prior radiation therapy and one prior line of alkylating chemotherapy for their disease.",
            "criterions": [
                {
                    "exact_snippets": "progressive disease after prior radiation therapy",
                    "criterion": "disease progression",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "progressive"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "after prior radiation therapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "one prior line of alkylating chemotherapy for their disease",
                    "criterion": "prior alkylating chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": "=",
                                "value": 1,
                                "unit": "line"
                            }
                        },
                        {
                            "requirement_type": "chemotherapy type",
                            "expected_value": "alkylating"
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Participants with non-breast and non-gastric cancers must have HER2-overexpression (IHC 3+ or IHC 2+; as determined by local testing using current ASCO-CAP guidelines for gastric IHC scoring).",
            "criterions": [
                {
                    "exact_snippets": "Participants with non-breast and non-gastric cancers must have HER2-overexpression (IHC 3+ or IHC 2+; as determined by local testing using current ASCO-CAP guidelines for gastric IHC scoring)",
                    "criterion": "HER2-overexpression",
                    "requirements": [
                        {
                            "requirement_type": "IHC score",
                            "expected_value": [
                                "3+",
                                "2+"
                            ]
                        },
                        {
                            "requirement_type": "testing method",
                            "expected_value": "local testing using current ASCO-CAP guidelines for gastric IHC scoring"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have evaluable disease.",
            "criterions": [
                {
                    "exact_snippets": "Participants must have evaluable disease.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "evaluability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1 .",
            "criterions": [
                {
                    "exact_snippets": "Participants must have evaluable disease: at least one measurable and/or non-measurable lesions per RECIST 1.1",
                    "criterion": "evaluable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least one measurable and/or non-measurable lesions per RECIST 1.1",
                    "criterion": "lesions (per RECIST 1.1)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": [
                                "measurable",
                                "non-measurable"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have progressed following at least one prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment option.",
            "criterions": [
                {
                    "exact_snippets": "progressed following at least one prior systemic treatment for metastatic or advanced disease",
                    "criterion": "disease progression after prior systemic treatment",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number_of_prior_systemic_treatments",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "treatment"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "no satisfactory alternative treatment option",
                    "criterion": "alternative treatment options",
                    "requirements": [
                        {
                            "requirement_type": "satisfactory_alternative_treatment_option",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must be capable of eating a high fat meal and adhering to fasting restrictions.",
            "criterions": [
                {
                    "exact_snippets": "capable of eating a high fat meal",
                    "criterion": "ability to eat a high fat meal",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "adhering to fasting restrictions",
                    "criterion": "ability to adhere to fasting restrictions",
                    "requirements": [
                        {
                            "requirement_type": "capability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-sterilised male participants who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to approximately 6 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Non-sterilised male participants",
                    "criterion": "male sterilization status",
                    "requirements": [
                        {
                            "requirement_type": "sterilization status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "sexually active with a female partner of childbearing potential",
                    "criterion": "sexual activity with female partner of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sexual activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "partner childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use a condom with spermicide from screening to approximately 6 months after the last dose of study intervention",
                    "criterion": "condom with spermicide use",
                    "requirements": [
                        {
                            "requirement_type": "use of condom with spermicide",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening to approximately 6 months after the last dose of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants recruited specifically for PD evaluation must have at least 1 tumour suitable for paired biopsies and be willing to consent to pre-treatment and on-treatment biopsies.",
            "criterions": [
                {
                    "exact_snippets": "Participants recruited specifically for PD evaluation must have at least 1 tumour suitable for paired biopsies",
                    "criterion": "tumour suitable for paired biopsies",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "tumour"
                            }
                        },
                        {
                            "requirement_type": "suitability for paired biopsies",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willing to consent to pre-treatment and on-treatment biopsies",
                    "criterion": "willingness to consent to biopsies",
                    "requirements": [
                        {
                            "requirement_type": "willingness to consent",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "biopsy timing",
                            "expected_value": [
                                "pre-treatment",
                                "on-treatment"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should have unresectable, or metastatic disease based on most recent imaging. The following tumour types are eligible for this study: TNBC, Endometrial cancer, Ovarian Cancer and CRPC.",
            "criterions": [
                {
                    "exact_snippets": "unresectable, or metastatic disease based on most recent imaging",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "unresectable",
                                "metastatic"
                            ]
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "most recent imaging"
                        }
                    ]
                },
                {
                    "exact_snippets": "The following tumour types are eligible for this study: TNBC, Endometrial cancer, Ovarian Cancer and CRPC",
                    "criterion": "tumour type",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "TNBC",
                                "Endometrial cancer",
                                "Ovarian Cancer",
                                "CRPC"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Male participants must refrain from fathering a child or donating sperm during the study and for approximately 6 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Male participants must refrain from fathering a child ... during the study and for approximately 6 months after the last dose of study intervention.",
                    "criterion": "fathering a child",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male participants must refrain from ... donating sperm during the study and for approximately 6 months after the last dose of study intervention.",
                    "criterion": "donating sperm",
                    "requirements": [
                        {
                            "requirement_type": "abstinence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. If sexually active with a non-sterilised male partner, must use at least one highly effective method of birth control in combination with one effective method (male condom plus spermicide) from screening until at least 7 months after the last dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "If sexually active with a non-sterilised male partner",
                    "criterion": "sexual activity with a non-sterilised male partner",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must use at least one highly effective method of birth control in combination with one effective method (male condom plus spermicide) from screening until at least 7 months after the last dose of study intervention",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "at least one highly effective method of birth control",
                                "one effective method (male condom plus spermicide)"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "from screening until at least 7 months after the last dose of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Must have a negative pregnancy test result at screening and prior to each cycle of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "negative pregnancy test result at screening",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "at screening"
                        }
                    ]
                },
                {
                    "exact_snippets": "negative pregnancy test result ... prior to each cycle of study treatment",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timepoint",
                            "expected_value": "prior to each cycle of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have metastatic or recurrent locally advanced histologically or cytologically confirmed Human Epidermal growth factor Receptor 2 (HER2)-negative carcinoma of the breast and evidence of a predicted loss of function germline or tumour mutation.",
            "criterions": [
                {
                    "exact_snippets": "metastatic or recurrent locally advanced ... carcinoma of the breast",
                    "criterion": "carcinoma of the breast",
                    "requirements": [
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "metastatic",
                                "recurrent locally advanced"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically or cytologically confirmed",
                    "criterion": "carcinoma confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Human Epidermal growth factor Receptor 2 (HER2)-negative",
                    "criterion": "HER2 status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation",
                    "criterion": "predicted loss of function mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        },
                        {
                            "requirement_type": "mutation effect",
                            "expected_value": "predicted loss of function"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential:",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants of childbearing potential:",
            "criterions": [
                {
                    "exact_snippets": "Female participants of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants must not breastfeed and must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment.",
            "criterions": [
                {
                    "exact_snippets": "Female participants must not breastfeed",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not donate or retrieve ova for their own use from screening to approximately 6 months after the last dose of study treatment",
                    "criterion": "ova donation or retrieval for own use",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from screening to approximately 6 months after the last dose of study treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "- Participants must have one of the following: (i) Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D (ii) Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease and evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed relapsed advanced ovarian, fallopian tube or primary peritoneal cancer",
                    "criterion": "ovarian, fallopian tube or primary peritoneal cancer",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": [
                                "ovarian cancer",
                                "fallopian tube cancer",
                                "primary peritoneal cancer"
                            ]
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically confirmed",
                                "cytologically confirmed"
                            ]
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "relapsed advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C or RAD51D",
                    "criterion": "homologous recombination repair gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation location",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "BRCA1",
                                "BRCA2",
                                "PALB2",
                                "RAD51C",
                                "RAD51D"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Histologically or cytologically confirmed HER2-negative carcinoma of the breast with recurrent locally advanced or metastatic disease",
                    "criterion": "HER2-negative breast carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": "carcinoma of the breast"
                        },
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histologically confirmed",
                                "cytologically confirmed"
                            ]
                        },
                        {
                            "requirement_type": "HER2 status",
                            "expected_value": "HER2-negative"
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "recurrent locally advanced",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of a predicted loss of function germline or tumour mutation in one of the following homologous recombination repair genes: BRCA1, BRCA2, PALB2, RAD51C, or RAD51D",
                    "criterion": "homologous recombination repair gene mutation",
                    "requirements": [
                        {
                            "requirement_type": "mutation type",
                            "expected_value": "predicted loss of function"
                        },
                        {
                            "requirement_type": "mutation location",
                            "expected_value": [
                                "germline",
                                "tumour"
                            ]
                        },
                        {
                            "requirement_type": "gene",
                            "expected_value": [
                                "BRCA1",
                                "BRCA2",
                                "PALB2",
                                "RAD51C",
                                "RAD51D"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Recurrent disease must be evaluable by MRI and at least 1 tumour of > 1cm diameter detected on MRI.",
            "criterions": [
                {
                    "exact_snippets": "Recurrent disease must be evaluable by MRI",
                    "criterion": "recurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "evaluability by MRI",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 tumour of > 1cm diameter detected on MRI",
                    "criterion": "tumour",
                    "requirements": [
                        {
                            "requirement_type": "number detected on MRI",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "tumour"
                            }
                        },
                        {
                            "requirement_type": "diameter",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "cm"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Participants with gastric cancer should be IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results.",
            "criterions": [
                {
                    "exact_snippets": "Participants with gastric cancer",
                    "criterion": "gastric cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "IHC 3+ or IHC 2+/ISH-positive based on local tissue testing results",
                    "criterion": "tumor HER2 status (by IHC/ISH)",
                    "requirements": [
                        {
                            "requirement_type": "IHC score",
                            "expected_value": "3+"
                        },
                        {
                            "requirement_type": "IHC score and ISH result",
                            "expected_value": [
                                "2+",
                                "ISH-positive"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Left ventricular ejection fraction (LVEF) ≥ 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "echocardiogram (ECHO)",
                                "multigated acquisition (MUGA) scan"
                            ]
                        },
                        {
                            "requirement_type": "measurement_timeframe",
                            "expected_value": "within 28 days before start of treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as ≥ 10 mm in the longest diameter.",
            "criterions": [
                {
                    "exact_snippets": "at least one lesion",
                    "criterion": "lesion",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "not previously irradiated",
                    "criterion": "lesion irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "previous irradiation",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "can be accurately measured at baseline as ≥ 10 mm in the longest diameter",
                    "criterion": "lesion size",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": ">=",
                                "value": 10,
                                "unit": "mm"
                            }
                        },
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female participants must not breastfeed and must not donate or retrieve ova for any use from screening to at least 7 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Female participants must not breastfeed ... from screening to at least 7 months after the last dose of study intervention.",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from screening to at least 7 months after the last dose of study intervention"
                        }
                    ]
                },
                {
                    "exact_snippets": "must not donate or retrieve ova for any use from screening to at least 7 months after the last dose of study intervention.",
                    "criterion": "ova donation or retrieval",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "from screening to at least 7 months after the last dose of study intervention"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any 2 participants in this panel must meet the following CNS criteria:",
            "criterions": [
                {
                    "exact_snippets": "Any 2 participants in this panel must meet the following CNS criteria",
                    "criterion": "CNS criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets CNS criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Known hypersensitivity to TMZ.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to TMZ",
                    "criterion": "hypersensitivity to TMZ",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants taking acid-reducing agents.",
            "criterions": [
                {
                    "exact_snippets": "Participants taking acid-reducing agents",
                    "criterion": "acid-reducing agent use",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a known hypersensitivity to T-DXd, any the excipients or other mAbs.",
            "criterions": [
                {
                    "exact_snippets": "known hypersensitivity to T-DXd",
                    "criterion": "hypersensitivity to T-DXd",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... any the excipients",
                    "criterion": "hypersensitivity to excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known hypersensitivity to ... other mAbs",
                    "criterion": "hypersensitivity to other monoclonal antibodies (mAbs)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with medical history of myocardial infarction. Participants with troponin levels above ULN at screening and without any myocardial related symptoms.",
            "criterions": [
                {
                    "exact_snippets": "medical history of myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "medical history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "troponin levels above ULN at screening",
                    "criterion": "troponin levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without any myocardial related symptoms",
                    "criterion": "myocardial related symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received > 1 prior line of alkylating chemotherapy regimen.",
            "criterions": [
                {
                    "exact_snippets": "> 1 prior line of alkylating chemotherapy regimen",
                    "criterion": "prior lines of alkylating chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received > 1 prior line of alkylating chemotherapy regimen.",
            "criterions": [
                {
                    "exact_snippets": "received > 1 prior line of alkylating chemotherapy regimen",
                    "criterion": "prior lines of alkylating chemotherapy regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 3",
            "criterions": [
                {
                    "exact_snippets": "Panel 3",
                    "criterion": "panel 3",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "All Panels",
            "criterions": [
                {
                    "exact_snippets": "All Panels",
                    "criterion": "panel inclusion",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": "all panels"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any evidence of severe or uncontrolled systemic diseases including active bleeding diatheses, active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV).",
            "criterions": [
                {
                    "exact_snippets": "Any evidence of severe or uncontrolled systemic diseases",
                    "criterion": "systemic diseases",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "active bleeding diatheses",
                    "criterion": "bleeding diatheses",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV)",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "human immunodeficiency virus (HIV)",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has history of non-infectious ILD/pneumonitis including radiation pneumonitis that required steroids, has current or suspected ILD/pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "history of non-infectious ILD/pneumonitis",
                    "criterion": "non-infectious ILD/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including radiation pneumonitis that required steroids",
                    "criterion": "radiation pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "has current or suspected ILD/pneumonitis",
                    "criterion": "ILD/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "suspected",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with an uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring IV antibiotics, antivirals, or antifungals",
                    "criterion": "infection treatment",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "IV antibiotics",
                                "IV antivirals",
                                "IV antifungals"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "History of (non-infectious) ILD/pneumonitis that required steroids",
                    "criterion": "history of non-infectious ILD/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "steroid requirement",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has current ILD/pneumonitis",
                    "criterion": "current ILD/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "suspected ILD/pneumonitis",
                    "criterion": "suspected ILD/pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "suspected presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or hepatitis C infection.",
            "criterions": [
                {
                    "exact_snippets": "Active primary immunodeficiency",
                    "criterion": "primary immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known uncontrolled active HIV infection",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "awareness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or hepatitis C infection",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "active hepatitis B or hepatitis C infection",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received bevacizumab within the last 6 months.",
            "criterions": [
                {
                    "exact_snippets": "received bevacizumab within the last 6 months",
                    "criterion": "bevacizumab administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness within the last 12 months.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness within the last 12 months.",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with HER2 directed TOPO1i ADCs and prior AZD9574 is not permitted.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with HER2 directed TOPO1i ADCs ... is not permitted.",
                    "criterion": "prior treatment with HER2 directed TOPO1i ADCs",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "prior AZD9574 is not permitted.",
                    "criterion": "prior treatment with AZD9574",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who had previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "previously experienced Grade 4 haematological toxicities ... during prior alkylating chemotherapy",
                    "criterion": "haematological toxicities",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 4"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during prior alkylating chemotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 3 neutropenia associated with infections ... during prior alkylating chemotherapy",
                    "criterion": "neutropenia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "association",
                            "expected_value": "with infections"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during prior alkylating chemotherapy"
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "association",
                            "expected_value": "with clinically significant bleeding"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during prior alkylating chemotherapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or prior use of immunosuppressive medication within 14 days before the first dose of T-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.",
            "criterions": [
                {
                    "exact_snippets": "Current or prior use of immunosuppressive medication within 14 days before the first dose of T-DXd",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within 14 days before first dose of T-DXd",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent ... within 4 weeks",
                    "criterion": "continuous corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/day or equivalent"
                            }
                        },
                        {
                            "requirement_type": "use within 4 weeks before first dose of T-DXd",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received a PARPi previously.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received a PARPi previously",
                    "criterion": "prior PARP inhibitor (PARPi) treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who suffer from claustrophobia.",
            "criterions": [
                {
                    "exact_snippets": "Participants who suffer from claustrophobia",
                    "criterion": "claustrophobia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any concurrent anti-cancer therapy or concurrent use of prohibited medications.",
            "criterions": [
                {
                    "exact_snippets": "Any concurrent anti-cancer therapy",
                    "criterion": "concurrent anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent use of prohibited medications",
                    "criterion": "concurrent use of prohibited medications",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen .",
            "criterions": [
                {
                    "exact_snippets": "received > one prior line of therapy in any setting with a PARPi-based regimen",
                    "criterion": "prior lines of therapy with PARPi-based regimen",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "regimen type",
                            "expected_value": "PARPi-based"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Corticosteroid mouthwash formulations are permitted to prevent and manage certain AEs.",
            "criterions": [
                {
                    "exact_snippets": "Corticosteroid mouthwash formulations are permitted",
                    "criterion": "corticosteroid mouthwash formulations",
                    "requirements": [
                        {
                            "requirement_type": "permitted use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any known predisposition to bleeding.",
            "criterions": [
                {
                    "exact_snippets": "Any known predisposition to bleeding",
                    "criterion": "predisposition to bleeding",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with an International Normalised Ratio (INR) >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.",
            "criterions": [
                {
                    "exact_snippets": "International Normalised Ratio (INR) >1.5",
                    "criterion": "International Normalised Ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": ""
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless the patient is receiving non-vitamin K antagonist oral anticoagulants",
                    "criterion": "non-vitamin K antagonist oral anticoagulant use",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a known history of prior platelet transfusion(s) or febrile neutropenia in the advanced disease treatment setting.",
            "criterions": [
                {
                    "exact_snippets": "known history of prior platelet transfusion(s)",
                    "criterion": "prior platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "febrile neutropenia in the advanced disease treatment setting",
                    "criterion": "febrile neutropenia in the advanced disease treatment setting",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Radiotherapy with a wide field of radiation within 4 weeks ... of the first dose of study intervention.",
                    "criterion": "radiotherapy with a wide field of radiation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study intervention.",
                    "criterion": "radiotherapy with a limited field of radiation for palliation",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe hypersensitivity reactions to other monoclonal antibodies.",
            "criterions": [
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to other monoclonal antibodies",
                    "criterion": "hypersensitivity reactions to other monoclonal antibodies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is pregnant or breastfeeding or planning to become pregnant.",
            "criterions": [
                {
                    "exact_snippets": "Participant is pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnant",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "breastfeeding",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "planning to become pregnant",
                    "criterion": "pregnancy intention",
                    "requirements": [
                        {
                            "requirement_type": "planning to become pregnant",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pleural effusion, ascites or pericardial effusion that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy.",
            "criterions": [
                {
                    "exact_snippets": "Pleural effusion ... that requires drainage",
                    "criterion": "pleural effusion",
                    "requirements": [
                        {
                            "requirement_type": "requires drainage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ascites ... that requires drainage, peritoneal shunt, or Cell-free and Concentrated Ascites Reinfusion Therapy",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "requires drainage",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires peritoneal shunt",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires Cell-free and Concentrated Ascites Reinfusion Therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pericardial effusion that requires drainage",
                    "criterion": "pericardial effusion",
                    "requirements": [
                        {
                            "requirement_type": "requires drainage",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "(d) Participants should not have received more than 2 prior lines of systemic cytotoxic therapy (e) Prior treatment with PARPi is permitted (f) Prior TOPO1 inhibitor therapy is NOT permitted (g) Prior treatment with TROP2-directed ADCs is NOT permitted. (h) Prior radiation therapy requires the washout periods.",
            "criterions": [
                {
                    "exact_snippets": "should not have received more than 2 prior lines of systemic cytotoxic therapy",
                    "criterion": "prior lines of systemic cytotoxic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with PARPi is permitted",
                    "criterion": "prior treatment with PARPi",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior TOPO1 inhibitor therapy is NOT permitted",
                    "criterion": "prior TOPO1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior treatment with TROP2-directed ADCs is NOT permitted",
                    "criterion": "prior treatment with TROP2-directed ADCs",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior radiation therapy requires the washout periods",
                    "criterion": "prior radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "washout period",
                            "expected_value": "required"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with implanted metal devices or implants containing metal",
            "criterions": [
                {
                    "exact_snippets": "Participants with implanted metal devices",
                    "criterion": "implanted metal devices",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "implants containing metal",
                    "criterion": "implants containing metal",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received a PARPi previously.",
            "criterions": [
                {
                    "exact_snippets": "Participants who have received a PARPi previously",
                    "criterion": "prior PARP inhibitor (PARPi) treatment",
                    "requirements": [
                        {
                            "requirement_type": "history of treatment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another primary malignancy.",
            "criterions": [
                {
                    "exact_snippets": "History of another primary malignancy.",
                    "criterion": "history of another primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with leptomeningeal disease (LMD) unless the LMD is of low volume or is previously treated and the participant is asymptomatic or minimal symptoms.",
            "criterions": [
                {
                    "exact_snippets": "Participants with leptomeningeal disease (LMD) unless the LMD is of low volume or is previously treated and the participant is asymptomatic or minimal symptoms.",
                    "criterion": "leptomeningeal disease (LMD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "volume or prior treatment and symptom status",
                            "expected_value": "LMD must be of low volume OR previously treated AND participant is asymptomatic or has minimal symptoms"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Additional lung-related exclusion criteria: (a) Lung-specific intercurrent clinically significant illnesses (b) Any autoimmune, connective tissue or inflammatory disorders (c) Prior pneumonectomy.",
            "criterions": [
                {
                    "exact_snippets": "Lung-specific intercurrent clinically significant illnesses",
                    "criterion": "lung-specific intercurrent clinically significant illnesses",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Any autoimmune, connective tissue or inflammatory disorders",
                    "criterion": "autoimmune, connective tissue or inflammatory disorders",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior pneumonectomy",
                    "criterion": "prior pneumonectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with leptomeningeal disease (LMD)",
            "criterions": [
                {
                    "exact_snippets": "Participants with leptomeningeal disease (LMD)",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe brain injury or stroke.",
            "criterions": [
                {
                    "exact_snippets": "History of severe brain injury",
                    "criterion": "severe brain injury",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... stroke",
                    "criterion": "stroke",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known allergy or hypersensitivity to investigational product(s) or any of the excipients of the investigational product(s).",
            "criterions": [
                {
                    "exact_snippets": "Known allergy or hypersensitivity to investigational product(s)",
                    "criterion": "allergy or hypersensitivity to investigational product(s)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "allergy or hypersensitivity to ... any of the excipients of the investigational product(s)",
                    "criterion": "allergy or hypersensitivity to excipients of investigational product(s)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Spinal cord compression unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Spinal cord compression unless asymptomatic, treated and stable",
                    "criterion": "spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "asymptomatic",
                                "treated",
                                "stable"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "not requiring continuous corticosteroids at a dose of > 10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention",
                    "criterion": "continuous corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/day or equivalent"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "requirement",
                            "expected_value": "not required"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 2",
            "criterions": [
                {
                    "exact_snippets": "Panel 2",
                    "criterion": "panel 2",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Positive Allen's test",
            "criterions": [
                {
                    "exact_snippets": "Positive Allen's test",
                    "criterion": "Allen's test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants currently on ARA treatment.",
            "criterions": [
                {
                    "exact_snippets": "Participants currently on ARA treatment",
                    "criterion": "ARA treatment",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any known history of persisting severe pancytopenia due to any cause.",
            "criterions": [
                {
                    "exact_snippets": "Any known history of persisting severe pancytopenia",
                    "criterion": "persisting severe pancytopenia",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of severe hypersensitivity reactions to Dato-DXd, or any of the excipients of the product.",
            "criterions": [
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to Dato-DXd",
                    "criterion": "hypersensitivity reactions to Dato-DXd",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of severe hypersensitivity reactions to ... any of the excipients of the product",
                    "criterion": "hypersensitivity reactions to excipients of the product",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Part A:",
            "criterions": [
                {
                    "exact_snippets": "Part A",
                    "criterion": "study part",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": "Part A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known contra-indication to gadolinium-enhanced Magnetic Resonance Imaging (MRI) or, if applicable, not able to be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 7 days) prior to the baseline MRI.",
            "criterions": [
                {
                    "exact_snippets": "Known contra-indication to gadolinium-enhanced Magnetic Resonance Imaging (MRI)",
                    "criterion": "contra-indication to gadolinium-enhanced MRI",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "not able to be maintained on a stable or decreasing dose of corticosteroid regimen (no increase for 7 days) prior to the baseline MRI",
                    "criterion": "corticosteroid regimen dose stability",
                    "requirements": [
                        {
                            "requirement_type": "dose stability",
                            "expected_value": "stable or decreasing"
                        },
                        {
                            "requirement_type": "duration of stability",
                            "expected_value": {
                                "operator": ">=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior anti-cancer treatments:",
            "criterions": [
                {
                    "exact_snippets": "Prior anti-cancer treatments",
                    "criterion": "prior anti-cancer treatments",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with LMD",
            "criterions": [
                {
                    "exact_snippets": "Participants with LMD",
                    "criterion": "leptomeningeal disease (LMD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to TMZ or dacarbazine or known history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9574.",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to TMZ",
                    "criterion": "hypersensitivity to TMZ",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hypersensitivity to ... dacarbazine",
                    "criterion": "hypersensitivity to dacarbazine",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD9574",
                    "criterion": "allergic reactions to compounds of similar chemical or biologic composition to AZD9574",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Presence of unresolved toxicities from previous anti-cancer therapy, defined as toxicities not yet resolved to Grade ≤ 1 or baseline.",
            "criterions": [
                {
                    "exact_snippets": "Presence of unresolved toxicities from previous anti-cancer therapy",
                    "criterion": "unresolved toxicities from previous anti-cancer therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "toxicities not yet resolved to Grade ≤ 1 or baseline",
                    "criterion": "toxicity grade",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "Grade"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": "baseline"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of uncontrolled seizures or with need for concurrent administration of more than 2 antiepileptic drugs, or history of epileptic disorder or any seizure history unrelated to tumour.",
            "criterions": [
                {
                    "exact_snippets": "History of uncontrolled seizures",
                    "criterion": "seizure history",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "need for concurrent administration of more than 2 antiepileptic drugs",
                    "criterion": "antiepileptic drug use",
                    "requirements": [
                        {
                            "requirement_type": "number of concurrent antiepileptic drugs",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "antiepileptic drugs"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "history of epileptic disorder",
                    "criterion": "epileptic disorder history",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "any seizure history unrelated to tumour",
                    "criterion": "seizure history unrelated to tumour",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants should not have received more than 2 prior lines of systemic cytotoxic therapy.",
            "criterions": [
                {
                    "exact_snippets": "should not have received more than 2 prior lines of systemic cytotoxic therapy",
                    "criterion": "prior lines of systemic cytotoxic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically severe pulmonary function compromise.",
            "criterions": [
                {
                    "exact_snippets": "Clinically severe pulmonary function compromise",
                    "criterion": "pulmonary function",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically severe"
                        },
                        {
                            "requirement_type": "compromise",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Panel 1",
            "criterions": [
                {
                    "exact_snippets": "Panel 1",
                    "criterion": "panel 1",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who had previously experienced Grade 4 haematological toxicities or Grade 3 neutropenia associated with infections, or Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy.",
            "criterions": [
                {
                    "exact_snippets": "previously experienced Grade 4 haematological toxicities ... during prior alkylating chemotherapy",
                    "criterion": "haematological toxicities during prior alkylating chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 4"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 3 neutropenia associated with infections ... during prior alkylating chemotherapy",
                    "criterion": "neutropenia during prior alkylating chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "association",
                            "expected_value": "with infections"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Grade 3 thrombocytopenia with clinically significant bleeding during prior alkylating chemotherapy",
                    "criterion": "thrombocytopenia during prior alkylating chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "Grade 3"
                        },
                        {
                            "requirement_type": "association",
                            "expected_value": "with clinically significant bleeding"
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must not enter the study if they received chloroquine / hydroxychloroquine < 14 days prior to the first dose.",
            "criterions": [
                {
                    "exact_snippets": "received chloroquine / hydroxychloroquine < 14 days prior to the first dose",
                    "criterion": "prior chloroquine or hydroxychloroquine use",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of another primary malignancy.",
            "criterions": [
                {
                    "exact_snippets": "History of another primary malignancy.",
                    "criterion": "history of another primary malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants who have received bevacizumab within the last 6 months.",
            "criterions": [
                {
                    "exact_snippets": "received bevacizumab within the last 6 months",
                    "criterion": "bevacizumab administration",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must not enter the study if they received chloroquine/hydroxychloroquine < 14 days prior to the first dose.",
            "criterions": [
                {
                    "exact_snippets": "received chloroquine/hydroxychloroquine < 14 days prior to the first dose",
                    "criterion": "chloroquine/hydroxychloroquine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Not requiring continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Not requiring continuous corticosteroids at a dose of >10 mg prednisone/day or equivalent for at least 4 weeks prior to start of study intervention.",
                    "criterion": "corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "requirement",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/day"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Clinically significant corneal disease.",
            "criterions": [
                {
                    "exact_snippets": "Clinically significant corneal disease",
                    "criterion": "corneal disease",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen.",
            "criterions": [
                {
                    "exact_snippets": "received > one prior line of therapy in any setting with a PARPi-based regimen",
                    "criterion": "prior lines of PARPi-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        },
                        {
                            "requirement_type": "regimen type",
                            "expected_value": "PARPi-based"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks of the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks of the first dose of study intervention.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation to study intervention",
                            "expected_value": "before first dose"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with a BMI > 30.0 kg/m2 or body weight > 100.0 kg",
            "criterions": [
                {
                    "exact_snippets": "BMI > 30.0 kg/m2",
                    "criterion": "BMI",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30.0,
                                "unit": "kg/m2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "body weight > 100.0 kg",
                    "criterion": "body weight",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 100.0,
                                "unit": "kg"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with an INR >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants.",
            "criterions": [
                {
                    "exact_snippets": "INR >1.5 unless the patient is receiving non-vitamin K antagonist oral anticoagulants",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": ""
                            }
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "receiving non-vitamin K antagonist oral anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD9574.",
            "criterions": [
                {
                    "exact_snippets": "Refractory nausea and vomiting",
                    "criterion": "nausea and vomiting",
                    "requirements": [
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic gastrointestinal diseases",
                    "criterion": "gastrointestinal diseases",
                    "requirements": [
                        {
                            "requirement_type": "chronic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inability to swallow the formulated product",
                    "criterion": "ability to swallow formulated product",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "previous significant bowel resection that would preclude adequate absorption of AZD9574",
                    "criterion": "bowel resection",
                    "requirements": [
                        {
                            "requirement_type": "history of significant resection",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "effect on absorption of AZD9574",
                            "expected_value": "precludes adequate absorption"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Current or prior use of immunosuppressive medication within 14 days before the first dose of Dato-DXd and within 4 weeks for continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent.",
            "criterions": [
                {
                    "exact_snippets": "Current or prior use of immunosuppressive medication within 14 days before the first dose of Dato-DXd",
                    "criterion": "immunosuppressive medication use",
                    "requirements": [
                        {
                            "requirement_type": "use within specified time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 14,
                                        "unit": "days before first dose of Dato-DXd"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "continuous corticosteroids at a dose of approximately > 10 mg prednisone/day or equivalent ... within 4 weeks",
                    "criterion": "continuous corticosteroid use",
                    "requirements": [
                        {
                            "requirement_type": "use within specified time frame",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks before first dose of Dato-DXd"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg prednisone/day or equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study intervention.",
            "criterions": [
                {
                    "exact_snippets": "any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 at the time of starting study intervention",
                    "criterion": "toxicities from prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "CTCAE Grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "With the exception of alopecia",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "exception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with insulin-dependent diabetes.",
            "criterions": [
                {
                    "exact_snippets": "insulin-dependent diabetes",
                    "criterion": "diabetes",
                    "requirements": [
                        {
                            "requirement_type": "insulin dependence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with an INR >1.5",
            "criterions": [
                {
                    "exact_snippets": "INR >1.5",
                    "criterion": "INR",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML.",
            "criterions": [
                {
                    "exact_snippets": "Patients with myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML)",
                    "criterion": "myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "features suggestive of MDS/AML",
                    "criterion": "features suggestive of myelodysplastic syndrome (MDS) or acute myeloid leukaemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants that have received > one prior line of therapy in any setting with a PARPi-based regimen.",
            "criterions": [
                {
                    "exact_snippets": "received > one prior line of therapy in any setting with a PARPi-based regimen",
                    "criterion": "prior lines of PARPi-based therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "Module 1:",
            "criterions": []
        },
        {
            "line": "Module 4 & 5:",
            "criterions": []
        },
        {
            "line": "Module 3:",
            "criterions": []
        },
        {
            "line": "Module 5 :",
            "criterions": []
        },
        {
            "line": "Module 4:",
            "criterions": []
        },
        {
            "line": "* Male participants must refrain from fathering a child or donating sperm during the study and for at least 4 months after the last dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Male participants must refrain from fathering a child during the study and for at least 4 months after the last dose of study intervention.",
                    "criterion": "fathering a child",
                    "requirements": [
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Male participants must refrain from ... donating sperm during the study and for at least 4 months after the last dose of study intervention.",
                    "criterion": "donating sperm",
                    "requirements": [
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "duration of study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "months after last dose"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Module 2:",
            "criterions": []
        }
    ],
    "failed_exclusion": [
        {
            "line": "Part B:",
            "criterions": []
        },
        {
            "line": "Module 3:",
            "criterions": []
        },
        {
            "line": "Module 5:",
            "criterions": []
        },
        {
            "line": "Module 2:",
            "criterions": []
        },
        {
            "line": "Module 4:",
            "criterions": []
        },
        {
            "line": "Module 1:",
            "criterions": []
        },
        {
            "line": "* Participants with LMD are excluded unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD.",
            "criterions": [
                {
                    "exact_snippets": "Participants with LMD are excluded unless the LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD.",
                    "criterion": "leptomeningeal disease (LMD)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "LMD is of low volume or is previously irradiated and the participant is asymptomatic from the LMD"
                        }
                    ]
                },
                {
                    "exact_snippets": "LMD is of low volume",
                    "criterion": "leptomeningeal disease (LMD) volume",
                    "requirements": [
                        {
                            "requirement_type": "volume",
                            "expected_value": "low"
                        }
                    ]
                },
                {
                    "exact_snippets": "LMD is previously irradiated",
                    "criterion": "leptomeningeal disease (LMD) irradiation status",
                    "requirements": [
                        {
                            "requirement_type": "irradiation status",
                            "expected_value": "previously irradiated"
                        }
                    ]
                },
                {
                    "exact_snippets": "participant is asymptomatic from the LMD",
                    "criterion": "leptomeningeal disease (LMD) symptoms",
                    "requirements": [
                        {
                            "requirement_type": "symptoms",
                            "expected_value": false
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}